Complete remission of ALK-negative plasma cell granuloma (inflammatory myofibroblastic tumor) of the lung induced by celecoxib: A case report and review of the literature

Chavez,Cinderella; Hoffman,Mark  A.

doi:10.3892/ol.2013.1260

Complete remission of ALK-negative plasma cell granuloma (inflammatory myofibroblastic tumor) of the lung induced by celecoxib: A case report and review of the literature

Authors:
- Cinderella Chavez
- Mark A. Hoffman
View Affiliations

Affiliations: Division of Hematology-Oncology, Department of Medicine, Long-Island Jewish Medical Center, North Shore-LIJ Health System, New Hyde Park, NY 11040, USA
Published online on: March 15, 2013 https://doi.org/10.3892/ol.2013.1260
Pages: 1672-1676

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

We report a case in which a 52-year-old female developed a multifocal inflammatory myofibroblastic tumor (IMT) of the lung. The tumor did not overexpress the anaplastic lymphoma kinase (ALK) protein, indicating a lack of ALK rearrangement. The patient required two wedge resections in 15 months due to recurrent disease. Recurrence after the second surgery was treated with corticosteroids, which only led to a transient response (6 months). Introduction of celecoxib, a cyclooxygenase-2 inhibitor, induced a complete remission in the patient. Maintenance on celecoxib further led to a progression-free survival of 34 months. A literature review retrieved a total of eight case reports, comprising ten patients, of IMT of various anatomical sites successfully treated with non-steroidal anti-inflammatory agent (NSAID) therapy. Nine of the ten patients achieved durable complete remission. Remission occurred rapidly and persisted even after termination of NSAID therapy. Although such a successful outcome may only be achieved rarely, a trial of an NSAID should be considered in any patient in whom complete resection is not an option. Our case also demonstrates that NSAID therapy may be successful in a non-ALK rearranged tumor in which ALK inhibition is not an option.

View Figures

View References

1	Gleason BC and Hornick JL: Inflammatory myofibroblastic tumours: where are we now? J Clin Pathol. 61:428–437. 2008. View Article : Google Scholar : PubMed/NCBI
2	Coffin CM and Fletcher JA: Inflammatory myofibroblastic tumor. Fletcher CD, Unni KK and Mertens F; World Health Organization Classification of Tumors: Pathology and Genetics of Soft Tissue and Bone. IARC Press; Lyon: pp. 91–93. 2002
3	Coffin CM, Hornick JL and Fletcher CD; Inflammatory myoblastic tumor: Comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases. Am J Surg Pathol. 31:509–520. 2007.PubMed/NCBI
4	Kovach SJ, Fischer AC, Katzman PJ, Salloum RM, Ettinghausen SE, Madeb R and Koniaris LG: Inflammatory myofibroblastic tumors. J Surg Oncol. 94:385–391. 2006. View Article : Google Scholar : PubMed/NCBI
5	Coffin CM, Watterson J, Priest JR and Dehner LP: Extrapulmonary inflammatory myofibroblastic tumor (inflammatory pseudotumor). A clinicopathologic and immunohistochemical study of 84 cases. Am J Surg Pathol. 19:859–872. 1995. View Article : Google Scholar
6	Lee MH, Lee HB, Lee YC, Rhee YK, Lee EJ, Chung MJ, Jin GY, Kweon EY and Park SJ: Bilateral multiple inflammatory myofibroblastic tumors of the lung successfully treated with corticosteroids. Lung. 189:433–435. 2011. View Article : Google Scholar : PubMed/NCBI
7	Carswell C and Chataway J: The successful long-term management of an intracranial inflammatory myoblastic tumor with corticosteroids. Clin Neurol Neurosurg. 114:77–79. 2012. View Article : Google Scholar : PubMed/NCBI
8	Hakozaki Y, Katou M, Nakagawa K, Shirahama T and Matsumoto T: Improvement of inflammatory pseudotumor of the liver after nonsteroidal anti-inflammatory agent therapy. Am J Gastroenterol. 88:1121–1122. 1993.PubMed/NCBI
9	Imperato JP, Folkman J, Sagerman RH and Cassady JR: Treatment of plasma cell granuloma of the lung with radiation therapy. A report of two cases and review of the literature. Cancer. 57:2127–2129. 1986. View Article : Google Scholar : PubMed/NCBI
10	Bertocchini A, Lo Zupone C, Callea F, Gennari F, Serra A, Monti L and de Ville de Goyet J: Unresectable multifocal omental and peritoneal inflammatory myofibroblastic tumor in a child: revisiting the role of adjuvant therapy. J Pediatr Surg. 46:e17–e21. 2011. View Article : Google Scholar : PubMed/NCBI
11	Butrynski JE, D’Adamo DR, Hornick JL, Dal Cin P, Antonescu CR, Jhanwar SC, Ladanyi M, Capelletti M, Rodig SJ, Ramaiya N, Kwak EL, Clark JW, Wilner KD, Christensen JG, Jänne PA, Maki RG, Demetri GD and Shapiro GI: Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. New Engl J Med. 363:1727–1733. 2010. View Article : Google Scholar : PubMed/NCBI
12	Su W, Ko A, O’Connell TX and Applebaum H: J Pediatr Surg. 35:1635–1637. 2000. View Article : Google Scholar
13	Chan PW, Omar KZ and Ramanujam TM: Successful treatment of unresectable inflammatory pseudotumor of the lung with COX-2 inhibitor. Pediatr Pulmonol. 36:167–169. 2003. View Article : Google Scholar : PubMed/NCBI
14	Przkora R, Bolder U, Schwartz S, Jauch KW, Spes J, Andreeson R and Mackensen A: Regression of nonresectable inflammatory myofibroblastic tumours after treatment with nonsteroidal anti-inflammatory drugs. Eur J Clin Invest. 34:320–321. 2004. View Article : Google Scholar : PubMed/NCBI
15	Colakoglu O, Unsal B, Haciyanli M, Tunakan M, Buyrac Z, Yorukoglu G, Yazicioglu N and Genc H: A successfully managed inflammatory pseudotumor of liver without surgery: report of a case. Acta Gastroenterol Belg. 68:382–384. 2005.PubMed/NCBI
16	Vassiliadis T, Vougiouklis N, Patsiaoura K, Mpoumponaris A, Nikolaidis N, Giouleme O and Evgenidis N: Inflammatory pseudotumor of the liver successfully treated with nonsteroidal anti-inflammatory drugs: a challenge diagnosis for one not so rare entity. Eur J Gastroenterol Hepatol. 19:1016–1020. 2007. View Article : Google Scholar : PubMed/NCBI
17	Mattei P and Barnaby K: Rapid regression of duodenal inflammatory myofibroblastic tumor after intravenous ketorolac: case report and review of the literature. J Pediatr Surg. 43:1196–1199. 2008. View Article : Google Scholar : PubMed/NCBI
18	Colangelo M, Lisi G and Chiesa PL: Pancreatic inflammatory myofibroblastic tumor (IMT). J Pediatr Surg. 45:1074–1075. 2009.PubMed/NCBI
19	Liao Z, Mason K and Milas L: Cyclo-oxygenase-2 and its inhibition in cancer. Drugs. 67:821–846. 2007. View Article : Google Scholar : PubMed/NCBI
20	Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, Edwards DA, Flickinger AG, Moore RJ and Seibert K: Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. 60:1306–1311. 2000.PubMed/NCBI
21	Applebaum H, Kieran MW, Cripe TP, Coffin C, Collins MH, Kaipainen A, Laforme A and Shamberger RC: The rationale for nonsteroidal anti-inflammatory drug therapy for inflammatory myofibroblastic tumors: a Children’s Oncology Group Study. J Pediatr Surg. 40:999–1003. 2005.PubMed/NCBI